Regentis Biomaterials Ltd. (RGNT)Healthcare | Medical Instruments & Supplies | Herzliya, Israel | NYSE American
3.47 USD
-0.32
(-8.443%) ⇩
(July 13, 2026, 4 p.m.
EDT)
After hours: 3.48 +0.01 (0.288%) ⇧ (July 13, 2026, 7:30 p.m. EDT) |
Hot Take ↕ | July 11, 2026, 6:58 a.m. EDT
The stock is currently trapped in a volatile, speculative frenzy driven by a single catalyst—the European rollout of GelrinC—rather than sustainable business fundamentals. While the price has surged significantly in the immediate past, the underlying reality is stark: the company reports negative earnings per share of -$25.16, negative return on assets, and a trailing P/E that is mathematically undefined due to these losses. The balance sheet shows negative operating cash flow, indicating the business is burning cash despite reporting positive free cash flow, likely due to accounting classifications rather than operational liquidity. With no analyst coverage, no dividend history, and a massive gap between the current price and the 52-week low, the recent volatility appears to be a classic 'pump' scenario where retail traders are chasing a narrative without a financial safety net. The statistical forecasting models correctly flag extreme uncertainty, reflecting the lack of reliable data to predict the next move. For a long-term investor, the absence of multi-year price history combined with deteriorating operational metrics makes this a hold-neutral position at best, as the current valuation offers no margin of safety against the inevitable correction if the product rollout fails to meet lofty expectations. |
| Model | MAE |
|---|---|
| AutoTheta ✓ | 0.233994 |
| MSTL | 0.243476 |
| AutoARIMA | 0.252005 |
| AutoETS | 0.253408 |
Forecast horizon: 60 days | Selected: AutoTheta
| Forecast Reliability | |
|---|---|
| Score | 14% |
| H-stat | 38.80 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.000 |
| Excess Kurtosis | 3.50 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 25.232 |
| Market Cap | 24,373,006 |
| Website | https://www.regentis.co.il |
| Attribute | Value |
|---|---|
| 52 Week Change | -0.4946667 |
| Address1 | 60, Medinat Hayehudim |
| Address2 | Entrance C Herzlia Pituach |
| All Time High | 15.5 |
| All Time Low | 1.232 |
| Ask | 0.0 |
| Ask Size | 300 |
| Average Daily Volume10 Day | 190,850 |
| Average Daily Volume3 Month | 5,454,929 |
| Average Volume | 5,454,929 |
| Average Volume10Days | 190,850 |
| Bid | 0.0 |
| Bid Size | 200 |
| Book Value | 0.916 |
| City | Herzliya |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Country | Israel |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 3.47 |
| Current Ratio | 2.651 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,782,777,600 |
| Day High | 3.75 |
| Day Low | 3.41 |
| Debt To Equity | 25.232 |
| Display Name | Regentis Biomaterials |
| Ebitda Margins | 0.0 |
| Enterprise Value | 11,791,442 |
| Eps Current Year | -0.68 |
| Eps Trailing Twelve Months | -22.12 |
| Esg Populated | 0 |
| Exchange | ASE |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 2.9217 |
| Fifty Day Average Change | 0.5483 |
| Fifty Day Average Change Percent | 0.18766473 |
| Fifty Two Week Change Percent | -49.46667 |
| Fifty Two Week High | 15.5 |
| Fifty Two Week High Change | -12.03 |
| Fifty Two Week High Change Percent | -0.776129 |
| Fifty Two Week Low | 1.232 |
| Fifty Two Week Low Change | 2.238 |
| Fifty Two Week Low Change Percent | 1.8165584 |
| Fifty Two Week Range | 1.232 - 15.5 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,764,858,600,000 |
| Float Shares | 2,821,725 |
| Free Cashflow | 3,029,625 |
| Full Exchange Name | NYSE American |
| Gmt Off Set Milliseconds | -14,400,000 |
| Gross Margins | 0.0 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.19047001 |
| Held Percent Institutions | 0.2849 |
| Implied Shares Outstanding | 7,023,921 |
| Industry | Medical Instruments & Supplies |
| Industry Disp | Medical Instruments & Supplies |
| Industry Key | medical-instruments-supplies |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Long Business Summary | Regentis Biomaterials Ltd., a regenerative medicine company, develops and commercializes tissue repair solutions in the United States. It offers Gelrin, a platform based on hydrogel matrix of polyethylene glycol diacrylate and denatured fibrinogen for the treatment and regeneration of damaged or diseased tissue; and GelrinC, a cell-free and off-the-shelf hydrogel, which is in Phase II clinical trial for the treatment of cartilage injuries in the knee. The company was incorporated in 2004 and is based in Herzliya, Israel. |
| Long Name | Regentis Biomaterials Ltd. |
| Market | us_market |
| Market Cap | 24,373,006 |
| Market State | PREPRE |
| Max Age | 86,400 |
| Message Board Id | finmb_13190555 |
| Most Recent Quarter | 1,767,139,200 |
| Net Income To Common | -13,692,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 24,373,005 |
| Number Of Analyst Opinions | 1 |
| Open | 3.79 |
| Operating Cashflow | -1,375,000 |
| Operating Margins | 0.0 |
| Payout Ratio | 0.0 |
| Phone | 972 9 960 1917 |
| Post Market Change | 0.00999999 |
| Post Market Change Percent | 0.28818417 |
| Post Market Price | 3.48 |
| Post Market Time | 1,783,985,411 |
| Previous Close | 3.79 |
| Price Eps Current Year | -5.102941 |
| Price Hint | 4 |
| Price To Book | 3.7882097 |
| Profit Margins | 0.0 |
| Quick Ratio | 2.647 |
| Quote Source Name | Delayed Quote |
| Quote Type | EQUITY |
| Recommendation Key | none |
| Region | US |
| Regular Market Change | -0.32 |
| Regular Market Change Percent | -8.44327 |
| Regular Market Day High | 3.75 |
| Regular Market Day Low | 3.41 |
| Regular Market Day Range | 3.41 - 3.75 |
| Regular Market Open | 3.79 |
| Regular Market Previous Close | 3.79 |
| Regular Market Price | 3.47 |
| Regular Market Time | 1,783,972,800 |
| Regular Market Volume | 70,404 |
| Return On Assets | -1.07531 |
| Sand P52 Week Change | 0.20847368 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Shares Outstanding | 7,023,921 |
| Shares Percent Shares Out | 0.020299999 |
| Shares Short | 143,052 |
| Shares Short Previous Month Date | 1,780,012,800 |
| Shares Short Prior Month | 25,580 |
| Short Name | Regentis Biomaterials Ltd. |
| Short Percent Of Float | 0.027999999 |
| Short Ratio | 0.01 |
| Source Interval | 15 |
| Symbol | RGNT |
| Target High Price | 10.0 |
| Target Low Price | 10.0 |
| Target Mean Price | 10.0 |
| Target Median Price | 10.0 |
| Total Cash | 7,378,000 |
| Total Cash Per Share | 1.424 |
| Total Debt | 1,197,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -22.12 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 4.197644 |
| Two Hundred Day Average Change | -0.7276442 |
| Two Hundred Day Average Change Percent | -0.17334585 |
| Type Disp | Equity |
| Volume | 70,404 |
| Website | https://www.regentis.co.il |
| Zip | 4,676,652 |